EP3567037A1 — N-((het)arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors
Assigned to Kalvista Pharmaceuticals Ltd · Expires 2019-11-13 · 7y expired
What this patent protects
The present invention provides a compound of formula (I):for use in a method of treatment of a disease or condition in which plasma kallikrein activity is implicated, wherein the disease or condition in which plasma kallikrein activity is implicated is hereditary angioedema.
USPTO Abstract
The present invention provides a compound of formula (I):for use in a method of treatment of a disease or condition in which plasma kallikrein activity is implicated, wherein the disease or condition in which plasma kallikrein activity is implicated is hereditary angioedema.
Drugs covered by this patent
- Ekterly (SEBETRALSTAT) · Kalvista
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.